Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the above subject application:

Listing of Claims:

1. (original) A compound of Formula I



Formula I

wherein

R is selected from the group consisting of OH, N_3, $-OR_1$, -O-aryl, -O-heteroaryl, $-OSO_2R_2$, $-NR_3R_4$, and



wherein

(i) R_1 is benzyl or C_{2-6}-acyl;

(ii) R_2 is selected from the group consisting of phenyl, tolyl, and C_{1-8}-alkyl; and

(iii) R_3 and R_4 are independently selected from the group consisting of hydrogen, C_{3-6}-cycloalkyl, phenyl, tert-butoxycarbonyl, fluorenyloxycarbonyl, benzyloxycarbonyl, $-CO_2-R_5$, $-CO-R_5$, $-CO-SR_5$, $-CS-R_5$, $P(O)(OR_6)(OR_7)$, $-SO_2-R_8$ and C_{1-6}-alkyl optionally substituted with 1 to 3 members independently selected from the group consisting of C_{1-5}-alkoxycarbonyl, OH, cyano, and halogen, wherein

R_5 is selected from the group consisting of hydrogen, C_{3-6}-cycloalkyl, trifluoromethyl, phenyl, benzyl, and C_{1-6}-alkyl optionally substituted with 1 to 3 members

independently selected from the group consisting of C_{1-5}-alkoxycarbonyl, OH, cyano, halogen, and $-NR_9R_{10}$ in which R_9 and R_{10} are independently selected from the group consisting of hydrogen, phenyl and C_{1-4}-alkyl;

R_6 and R_7 are independently hydrogen or C_{1-4}-alkyl; and

R_8 is phenyl or C_{1-4}-alkyl;

R_{11} is selected from the group consisting of hydrogen, alkyl, $-OR_{13}$, $-SR_{13}$, amino, $-NR_{13}R_{14}$, aryl(C_{1-8})alkyl, and mono-, di-, tri-, or per-halo C_{1-8}-alkyl;

R_{12} is selected from the group consisting of CN, $-COR_{13}$, $-COOR_{13}$, $-CO-NR_{13}R_{14}$, $-SO_2R_{13}$, $-SO_2-NR_{13}R_{14}$, and nitro; and

R_{13} and R_{14} are independently selected from the group consisting of hydrogen, alkyl, and aryl, or R_{13} and R_{14} taken together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group;

X is 0 to 4 members independently selected from the group consisting of halogen, OH, mercapto, nitro, halo-C_{1-8}-alkyl, C_{1-8}-alkoxy, C_{1-8}-alkylthio, C_{1-8}-alkyl-amino, di(C_{1-8}-alkyl)amino, formyl, carboxy, alkoxycarbonyl, C_{1-8} alkyl-CO-O-, C_{1-8} alkyl-CO-NH-, carboxamide, aryl, heteroaryl, CN, amino, C_{3-6}-cycloalkyl, C_{1-8}-alkyl optionally substituted with one or more members selected from the group consisting of F, Cl, OH, C_{1-8} alkoxy and C_{1-8} acyloxy; and

Y is a radical of Formula II:



Formula II

wherein

R_{15}, R_{16}, R_{17}, R_{18}, R_{19}, and R_{20} are each independently selected from the group consisting of hydrogen, CN, nitro, C_{1-8}-alkyl, halo-C_{1-8}-alkyl, formyl, carboxy, alkoxycarbonyl, carboxamide, aryl, and heteroaryl, or R_{15} and R_{16} and/or R_{17} and R_{18} and/or R_{19} and R_{20} together form an oxo group;

the moiety W represents any five- to ten-membered aromatic or heteroaromatic ring, said heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N;

Z is selected from the group consisting of hydrogen, halogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, CN, CHO, alkyl-CO-, alkoxy, (C_{1-8}-alkyl)-CONH-, and $R_{21}R_{22}N$-alkyl- wherein R_{21} and R_{22} are independently selected from the group consisting of hydrogen, C_{1-6}-alkyl, benzyl, aryl, and heteroaryl, or R_{21} and R_{22} together with the nitrogen to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group; and

m is 0 or 1

and the pharmaceutically acceptable salts and esters thereof.

2. (original) The compound of claim 1 wherein X is halogen.
hydrogen, alkyl, aryl, and heteroaryl.

3. (original) The compound of claim 1 wherein Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

4. (original) The compound of claim 1 wherein the moiety W is a fused phenyl ring or a five- or six-membered heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N.

5. (original) The compound of claim 1 wherein Y is selected from the group consisting of



wherein

Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, alkyl-CO-, and $R_{21}R_{22}N$-alkyl- wherein R_{21} and R_{22} are independently selected from the group consisting of hydrogen, C_{1-6}-alkyl, benzyl, aryl, and heteroaryl, or R_{21} and R_{22} together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group.

6. (original) The compound of claim 5 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

7. (original) The compound of claim 1 wherein R is selected from the group consisting of



8. (original) The compound of claim 6 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

9. (previously presented) A compound of Claim 1 having the formula:



10. (previously presented) A compound of Claim 1 having the formula:



11. (currently amended) A compound of Claim 1 having the formula:



12. (previously presented) A compound of Claim 1 having the formula:



13. (previously presented) A compound of Claim 1 having the formula:



14. (previously presented) A compound of Claim 1 having the formula:



15. (previously presented) A compound of Claim 1 having the formula:



16. (previously presented) A compound of Claim 1 having the formula:



17. (previously presented) A compound of Claim 1 having the formula:



18. (previously presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

19 and 20. (cancelled).

21. (previously presented) A method of treating a subject having a condition selected from the group consisting of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, bone and joint infections and hospital-acquired lung infections, said method comprising the step of administering to the subject a therapeutically effective amount of a compound according to claim 1.

22. (previously presented) The method of Claim 21 wherein said bacterium is selected from the group consisting of *S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes*, *Enterococcus spp.*, *Moraxella catarrhalis* and *H. influenzae.*

23. (previously presented) The method of Claim 21 wherein said bacterium is a Gram-positive coccus.

24. (original) The method of Claim 23 wherein said Gram-positive coccus is drug-resistant.

25 to 28. (canceled).